Wechselwirkungen · Plavix
Plavix 75 mg film-coated tablets Plavix 300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-087942 · Präparat HOS-083591
Inhibitors of CYP2C19 Since clopidogrel is metabolised to its active metabolite partly by CYP2C19, use of medicinal products that inhibit the activity of this enzyme would be expected to result in reduced drug levels of the active metabolite of clopidogrel. The clinical relevance of this interaction is uncertain. As a precaution concomitant use of strong or moderate CYP2C19 inhibitors should be discouraged (see sections 4.4 and 5.2).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-14T12:15:00Z · SHA-256 1e6a9d1e2861882ccf51f6506686a24b3c88e112fad66a7a9333c6e88547592c · Passage 00e4e34a3ec8d3a6821f58ee0e5998d522e148dccdfd971ee6e6b7d51436aafd · Zeichen 3778–4215 im Abschnitt